A commercially available chitosan (CS) was employed in the formulation of nanoparticles loaded with lysozyme (LZ) as antimicrobial protein drug model. Due to the variability of commercially available batches of chitosans and to the strict dependence of their physical and biological properties to the molecular weight (Mw) and deacetylation degree (DD) of the material, the CS was fully characterized resulting in weight-average molecular weight of 108,120g/mol and DD of 92%. LZ-loaded nanoparticles (LZ-NPs) of 150nm diameter were prepared by inotropic gelation. The nanoparticles were effectively preserving the antibacterial activity of the loaded enzyme, which was slowly released over 3 weeks in vitro and remained active toward Staphylococcus epidermidis up to 5 days of incubation. Beyond the intrinsic antibacterial activity of CS and LZ, the LZ-NPs evidenced a sustained antibacterial activity that resulted in about 2 log reduction of the number of viable S. epidermidis compared to plain CS nanoparticles. Furthermore, the LZ-NPs showed a full in vitro cytocompatibility toward murine fibroblasts and, in addition to the potential antimicrobial applications of the developed system, the proposed study could serve as an optimal model for development of CS nanoparticles carrying antimicrobial peptides for biomedical applications.
